.Pharmacolibrary.Drugs.V_Various.V09I_TumourDetection.V09IX02_Iobenguane131i.Iobenguane131i .Pharmacolibrary.Drugs.V_Various.V09I_TumourDetection.V09IX02_Iobenguane131i.Iobenguane131i| name: | Iobenguane131i | |
| ATC code: | V09IX02 | route: | intravenous |
| compartments: | 2 | |
| dosage: | 3700 | mg |
| volume of distribution: | 3.5 | L |
| clearance: | 0.18 | L/h/kg |
| other parameters in model implementation | ||
Iobenguane (131I), also known as 131I-metaiodobenzylguanidine (131I-MIBG), is a radiopharmaceutical agent used primarily for diagnostic imaging and treatment of certain types of neuroendocrine tumors, such as pheochromocytoma and neuroblastoma. It is labeled with radioactive iodine-131 and selectively taken up by adrenergic tissue. 131I-MIBG is currently approved for therapeutic use in metastatic or relapsed high-risk neuroblastoma.
Pharmacokinetic parameters as reported in adult patients undergoing therapy for neuroendocrine tumors; data from published clinical studies and product information.